Vaxdyn joins the BEAM alliance

According to the CDC, “antibiotic resistance is one of the most urgent threats to the public’s health”. Antibiotic resistance, also known as anti-microbial resistance (AMR), presents the pharmaceutical industry with an increasingly difficult task to discover and develop new antibiotics and therefore, alternative solutions to solve this issue are urgently required. Vaccines represent such an alternative since they help limit the spread of antibiotic-resistant bacteria by reducing the number of patients infected by the bacteria in the first place, thereby reducing the number of patients who go on a course of antibiotics.

                                                                              Acinetobacter Baumannii

Existing vaccines are useful of course, but there are many prevalent bacterial diseases for which no vaccine has yet been developed. According to the WHO, the 3 bacteria against which the fight should be prioritized are:

Vaxdyn, a Spanish company based in Seville (and a key member of the InSynchony Ventures investment portfolio) is developing a vaccine directed against Acinetobacter baumannii, WHO’s number 1 priority!

Earlier this year, Vaxdyn joined almost 50 other companies in BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) to strengthen their collaboration while they all develop novel products. Together, the BEAM Alliance members aim to influence and encourage the creation of new incentives to fast-track finding new tools to fight AMR.

InSynchrony is proud to be working closely with Vaxdyn in this exciting and essential field of bacterial vaccines and we will keep you updated as the story evolves.